Ajanta Pharma’s share price was trading higher on Friday ahead of the Q4 earnings that were released after market close.
What Happened: The pharma company’s revenue from operations was up marginally at ₹881.84 crore as against ₹870.29 crore in the corresponding quarter last year. The company’s international business was down hampering the overall revenue. The company spent ₹63 crore or 7% of revenue on R&D in the March quarter.
Total Branded Generic Business sales for the quarter ended March stood at ₹625 crore down 3% from ₹644 crore sales it reported in the same quarter last year. US Generic Business, on the other hand, saw an uptick of 17% at ₹197 crore compared to ₹168 crore in the March quarter of 2022.
EBITDA was down 28% year-over-year at ₹149 crore. Net profits for the review period slumped 19% YoY at ₹122.25 crore much below consensus estimates. Earnings per share for the quarter stood at ₹9.54.
Price Action: Ajanta Pharma’s share price jumped up 0.54% to close at ₹1,290 on Friday.
Get all the latest Share Market trends and news to set you up for the week ahead.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.